61 related articles for article (PubMed ID: 31396953)
21. Immunogenic cell stress and death.
Kroemer G; Galassi C; Zitvogel L; Galluzzi L
Nat Immunol; 2022 Apr; 23(4):487-500. PubMed ID: 35145297
[TBL] [Abstract][Full Text] [Related]
22. Targeting the "undruggable" RAS with biologics.
Whaby M; Khan I; O'Bryan JP
Adv Cancer Res; 2022; 153():237-266. PubMed ID: 35101232
[TBL] [Abstract][Full Text] [Related]
23. The immune modifying effects of chemotherapy and advances in chemo-immunotherapy.
Principe DR; Kamath SD; Korc M; Munshi HG
Pharmacol Ther; 2022 Aug; 236():108111. PubMed ID: 35016920
[TBL] [Abstract][Full Text] [Related]
24. Harnessing Antitumor CD4
Ben Khelil M; Godet Y; Abdeljaoued S; Borg C; Adotévi O; Loyon R
Cancers (Basel); 2022 Jan; 14(1):. PubMed ID: 35008422
[TBL] [Abstract][Full Text] [Related]
25. Immune microenvironment in patients with mismatch-repair-proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study.
Jary M; Liu WW; Yan D; Bai I; Muranyi A; Colle E; Brocheriou I; Turpin A; Radosevic-Robin N; Bourgoin P; Penault-Llorca F; Cohen R; Vernerey D; André T; Borg C; Shanmugam K; Svrcek M
Mol Oncol; 2022 Jun; 16(11):2260-2273. PubMed ID: 34954864
[TBL] [Abstract][Full Text] [Related]
26. Combined Treatment with Immunotherapy-Based Strategies for MSS Metastatic Colorectal Cancer.
Baraibar I; Mirallas O; Saoudi N; Ros J; Salvà F; Tabernero J; Élez E
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944931
[TBL] [Abstract][Full Text] [Related]
27. Abscopal Effect and Drug-Induced Xenogenization: A Strategic Alliance in Cancer Treatment?
Franzese O; Torino F; Giannetti E; Cioccoloni G; Aquino A; Faraoni I; Fuggetta MP; De Vecchis L; Giuliani A; Kaina B; Bonmassar E
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639014
[TBL] [Abstract][Full Text] [Related]
28. Targeting the KRAS α4-α5 allosteric interface inhibits pancreatic cancer tumorigenesis.
Khan I; Marelia-Bennet C; Lefler J; Zuberi M; Denbaum E; Koide A; Connor DM; Broome AM; Pécot T; Timmers C; Ostrowski MC; Koide S; O'Bryan JP
Small GTPases; 2022 Jan; 13(1):114-127. PubMed ID: 33949915
[No Abstract] [Full Text] [Related]
29. Empirical and Rational Design of T Cell Receptor-Based Immunotherapies.
Jones HF; Molvi Z; Klatt MG; Dao T; Scheinberg DA
Front Immunol; 2020; 11():585385. PubMed ID: 33569049
[TBL] [Abstract][Full Text] [Related]
30. Oxaliplatin induces the PARP1-mediated parthanatos in oral squamous cell carcinoma by increasing production of ROS.
Li D; Kou Y; Gao Y; Liu S; Yang P; Hasegawa T; Su R; Guo J; Li M
Aging (Albany NY); 2021 Jan; 13(3):4242-4257. PubMed ID: 33495407
[TBL] [Abstract][Full Text] [Related]
31. Treatment Strategies and Metabolic Pathway Regulation in Urothelial Cell Carcinoma: A Comprehensive Review.
Yang HY; Wu CY; Chen JJ; Lee TH
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33256165
[TBL] [Abstract][Full Text] [Related]
32. Anti-Telomerase CD4
Spehner L; Kim S; Vienot A; François E; Buecher B; Adotevi O; Vernerey D; Abdeljaoued S; Meurisse A; Borg C
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32957741
[TBL] [Abstract][Full Text] [Related]
33. Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge.
Marmorino F; Boccaccino A; Germani MM; Falcone A; Cremolini C
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32824490
[TBL] [Abstract][Full Text] [Related]
34. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors.
Galluzzi L; Humeau J; Buqué A; Zitvogel L; Kroemer G
Nat Rev Clin Oncol; 2020 Dec; 17(12):725-741. PubMed ID: 32760014
[TBL] [Abstract][Full Text] [Related]
35. Telomerase and CD4 T Cell Immunity in Cancer.
Dosset M; Castro A; Carter H; Zanetti M
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32630460
[TBL] [Abstract][Full Text] [Related]
36. Revisiting the role of CD4
Tay RE; Richardson EK; Toh HC
Cancer Gene Ther; 2021 Feb; 28(1-2):5-17. PubMed ID: 32457487
[TBL] [Abstract][Full Text] [Related]
37. CD4 T cells target colorectal cancer antigens upregulated by oxaliplatin.
Galaine J; Turco C; Vauchy C; Royer B; Mercier-Letondal P; Queiroz L; Loyon R; Mouget V; Boidot R; Laheurte C; Lakkis Z; Jary M; Adotévi O; Borg C; Godet Y
Int J Cancer; 2019 Dec; 145(11):3112-3125. PubMed ID: 31396953
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (
Combès E; Andrade AF; Tosi D; Michaud HA; Coquel F; Garambois V; Desigaud D; Jarlier M; Coquelle A; Pasero P; Bonnefoy N; Moreaux J; Martineau P; Del Rio M; Beijersbergen RL; Vezzio-Vie N; Gongora C
Cancer Res; 2019 Jun; 79(11):2933-2946. PubMed ID: 30987998
[TBL] [Abstract][Full Text] [Related]
39. miR-122 Targets X-Linked Inhibitor of Apoptosis Protein to Sensitize Oxaliplatin-Resistant Colorectal Cancer Cells to Oxaliplatin-Mediated Cytotoxicity.
Hua Y; Zhu Y; Zhang J; Zhu Z; Ning Z; Chen H; Liu L; Chen Z; Meng Z
Cell Physiol Biochem; 2018; 51(5):2148-2159. PubMed ID: 30522111
[TBL] [Abstract][Full Text] [Related]
40. Induction of both CD8+ and CD4+ T-cell-mediated responses in colorectal cancer patients by colon antigen-1.
Maccalli C; Di Cristanziano V; Fodale V; Corsi D; D'Agostino G; Petrangeli V; Laurenti L; Guida S; Mazzocchi A; Arienti F; Perrone MP; Castelli C; Rivoltini L; Zagonel V; Tartaglia M; Parmiani G; Belardelli F
Clin Cancer Res; 2008 Nov; 14(22):7292-303. PubMed ID: 18974390
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
